What Patients Should Know About Ozempic and Gastroparesis Symptoms

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Pharmacological Exposure

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal discomfort, you may be concerned about gastroparesis. Decades of pharmacovigilance have established that certain medications can slow gastric emptying, and recent reports highlight this risk with GLP-1 receptor agonists. This page outlines the symptoms to track and the evidence linking Ozempic to gastroparesis.

Understanding Gastroparesis and Ozempic's Mechanism

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath tests, and management focuses on dietary modifications, prokinetic agents, and antiemetics. The condition can significantly impair quality of life and may be idiopathic or secondary to diabetes, surgery, or medication use. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for cardiovascular risk reduction. Its pharmacology includes slowing gastric emptying, which contributes to its glucose-lowering effects but also underlies many gastrointestinal adverse reactions. The prescribing information for Ozempic documents that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed as an adverse reaction in these data, the mechanistic pathway linking Ozempic to gastroparesis is biologically plausible. GLP-1 receptor agonists delay gastric emptying via vagal and enteric nervous system pathways, and prolonged or severe delay can mimic or exacerbate gastroparesis symptoms. The reported gastrointestinal adverse reactions—nausea, vomiting, dyspepsia, and gastroesophageal reflux disease—overlap significantly with the clinical presentation of gastroparesis, raising the question of whether Ozempic can induce a gastroparesis-like syndrome or unmask underlying gastroparesis.

Risk Communication and Clinical Implications

Regarding risk considerations, the adequacy of warnings for Ozempic and gastroparesis is a key concern. The prescribing information includes warnings about gastrointestinal adverse reactions but does not specifically mention gastroparesis. Serious hypersensitivity reactions, such as anaphylaxis and angioedema, are addressed in the warnings and precautions section, but no dedicated warning exists for gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap may leave patients and clinicians unaware of the potential for severe gastric motility issues beyond typical nausea and vomiting. For affected patients, causation considerations are complex. The timeline between Ozempic exposure and documented harm is critical. Gastrointestinal adverse reactions often occur during dose escalation, suggesting a temporal relationship. However, gastroparesis may develop insidiously, and symptoms may persist or worsen even after dose stabilization. Patients with pre-existing diabetic gastroparesis may be particularly vulnerable, as Ozempic could exacerbate their condition. The absence of specific gastroparesis warnings in the label may delay diagnosis and appropriate management, such as dose reduction, discontinuation, or alternative therapies. In summary, while Ozempic is not explicitly labeled as causing gastroparesis, the evidence indicates a strong mechanistic link and a high incidence of overlapping gastrointestinal adverse reactions. The prescribing data show that gastrointestinal adverse reactions are common and dose-dependent, with discontinuation rates significantly higher than placebo. The lack of a specific gastroparesis warning represents a potential risk communication gap. Patients experiencing persistent or severe gastrointestinal symptoms while on Ozempic should be evaluated for gastroparesis, and clinicians should consider the drug's role in symptom causation. Further research is needed to clarify the incidence of confirmed gastroparesis in Ozempic users and to optimize risk mitigation strategies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can Ozempic cause gastroparesis?

While Ozempic is not explicitly labeled as causing gastroparesis, there is a strong mechanistic link. Ozempic slows gastric emptying, and gastrointestinal adverse reactions such as nausea, vomiting, and dyspepsia are common and dose-dependent. These symptoms overlap significantly with gastroparesis, raising the possibility that Ozempic can induce a gastroparesis-like syndrome or unmask underlying gastroparesis. The prescribing information does not include a specific warning for gastroparesis, which may delay diagnosis and management.

What are the gastrointestinal side effects of Ozempic?

According to the prescribing information, gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Common side effects include nausea, vomiting, diarrhea, dyspepsia, eructation, flatulence, gastroesophageal reflux disease, and gastritis. Discontinuation due to gastrointestinal issues was higher in Ozempic groups (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%).

How is gastroparesis diagnosed?

Gastroparesis is diagnosed through tests that measure gastric emptying, such as gastric emptying scintigraphy or breath tests. Symptoms include nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis requires excluding mechanical obstruction. If you experience persistent gastrointestinal symptoms while taking Ozempic, consult your healthcare provider for evaluation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.